Forest, Merz announce Namenda patent settlements
NEW YORK Several generic drug makers have settled with Forest Labs and German drug maker Merz Pharma GmbH & Co. concerning a drug used to treat Alzheimer’s disease, Forest and Merz said Thursday.
The two drug makers announced a settlement with Mylan, Watson Pharmaceuticals, Dr. Reddy’s Labs, Lupin Pharmaceuticals, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries, Amneal Pharmaceuticals and Upsher-Smith Labs regarding patent infringement litigation over the immediate-release formulation of the drug Namenda (memantine hydrochloride).
Under the agreements, the first generic versions of Namenda will appear in January 2015. The drug’s patent expires in April of that year.
Namenda had sales of $1.2 billion during the 12-month period ended in March, according to IMS Health.